Regulation of Mouse Retroelement MuERV-L/MERVL Expression by REX1 and Epigenetic Control of Stem Cell Potency by Jon Schoorlemmer et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 06 February 2014
doi: 10.3389/fonc.2014.00014
Regulation of mouse retroelement MuERV-L/MERVL
expression by REX1 and epigenetic control of stem cell
potency
Jon Schoorlemmer 1,2*, Raquel Pérez-Palacios1, María Climent 3†, Diana Guallar 1† and Pedro Muniesa3
1 Regenerative Medicine Program, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain
2 ARAID Foundation, Zaragoza, Spain
3 Departamento de Anatomía, Embriología y Genética Animal, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza, Spain
Edited by:
Iyoko Katoh, University of Yamanashi,
Japan
Reviewed by:
Sathish Kumar Mungamuri, Mount
Sinai School of Medicine, USA
Xiaoping Zhang, Mount Sinai School
of Medicine, USA
*Correspondence:
Jon Schoorlemmer , Centro de
Investigación Biomédica de Aragón
(CIBA), Avda. San Juan Bosco 13,
Planta A, Zaragoza 50009, Spain
e-mail: jschoorlemmer.iacs@
aragon.es
†Present address:
María Climent, Stem Cell Center,
Lund, Sweden;
Diana Guallar , Black Family Stem Cell
Institute, Icahn School of Medicine at
Mount Sinai, NewYork, USA
About half of the mammalian genome is occupied by DNA sequences that originate
from transposable elements. Retrotransposons can modulate gene expression in differ-
ent ways and, particularly retrotransposon-derived long terminal repeats, profoundly shape
expression of both surrounding and distant genomic loci. This is especially important in
pre-implantation development, during which extensive reprograming of the genome takes
place and cells pass through totipotent and pluripotent states. At this stage, the main mech-
anism responsible for retrotransposon silencing, i.e., DNA methylation, is inoperative. A
particular retrotransposon called muERV-L/MERVL is expressed during pre-implantation
stages and contributes to the plasticity of mouse embryonic stem cells. This review will
focus on the role of MERVL-derived sequences as controlling elements of gene expres-
sion specific for pre-implantation development, two-cell stage-specific gene expression,
and stem cell pluripotency, the epigenetic mechanisms that control their expression, and
the contributions of the pluripotency marker REX1 and the related Yin Yang 1 family of
transcription factors to this regulation process.
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INTRODUCTION
Transposable elements (TEs) are DNA sequences with the ability
to move from one chromosomal location to another. They were
discovered by McClintock (1), who was awarded the 1983 Nobel
Prize in Physiology or Medicine for this work. To explain color pat-
terns in maize kernels, she postulated that gene expression might
be regulated by “controlling elements” that could jump around the
genome [reviewed by Fedoroff (2)]. Initial drafts of both human
and mouse genomes indicated that about half of the mammalian
genomes are occupied by DNA sequences that originate from
TE (3). Posterior estimates are even higher up to two-thirds (4).
Among the TEs figure the endogenous retroviral elements (ERVs),
which make up about 10% of mammalian genomes. As opposed
to exogenous retrovirus, ERVs are an integral component of the
genome in all cells of an organism. ERVs are the remnants of
ancient retroviral infections of the germline that have produced
stable integrations in the genome, which are therefore passed on
to the offspring in a Mendelian fashion (5, 6). Expression of ERV
is usually repressed by mechanisms dependent on DNA methyla-
tion (7), and deregulation of human ERV (HERV) contributes
to disease (8). In contrast to other mammals like mouse and
cat, there exists no definitive proof for the presence of infectious
HERV particles, although ERV might be mobile even in human
(9). Therefore, HERV might contribute to tumor development
as retroviruses do (8), through HERV-encoded transcripts, or by
regulating expression of genes nearby or even at a distance. Indeed,
the expression of HERVs has been linked to a variety of tumors
(8, 10), although HERV has not presently been identified as an
etiological factor in tumor development.
Pluripotent self-renewing embryonic stem (ES) cells can be
derived from the inner cell mass (ICM) of the pre-implantation
blastocyst. Cells from earlier embryos (zygotes until eight-cell
embryos) differentiate into both fetal and placental cell types.
This ability is called totipotency as opposed to the more restricted
differentiation potential of pluripotent ICM cells, which only
contribute to embryonic tissue (11, 12). ES cells in culture are
heterogeneous (13, 14), and several of their characteristics can
best be understood in the context of successive changes occur-
ring during pre-implantation development, as the cells transition
between states that resemble cellular identities at distinct stages
of pre-implantation development. Mouse ES cells display special
epigenetic features such as a loose chromatin structure and altered
DNA methylation, which underlie their cell type-specific proper-
ties (15). Similar to the pre-implantation embryo, mouse ES cells
express several kinds of ERV, in line with the absence of DNA
methylation. Among the ERV expressed is MERVL, whose expres-
sion actually peaks in two-cell stage embryos (16). Importantly,
MERVL expression in mouse ES cells is restricted to a subpopu-
lation of the cells with special characteristics as defined by gene
expression and differentiation potential normally found in cells of
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two-cell embryos (17). Degenerated cis-acting elements derived
from MERVL elements are also essential to pluripotency-related
phenomena, i.e., re-activation of the second X-chromosome (18,
19), and we speculate on its role in developmental potency and
differentiation.
We will review how MERVL sequences drive gene expres-
sion restricted to different states of developmental potency in
mouse stem cells. These contributions depend on epigenetic reg-
ulation mechanisms exerted by protein complexes that modify
or read histone modifications, particularly Polycomb complexes
and demethylase complexes. REX1 is a pluripotency-associated
nuclear protein that binds MERVL elements in vivo, and a con-
tribution of REX1 to silencing of MERVL has been demonstrated
(20). REX1 reunites additional characteristics consistent with a
role in orchestrating how regulatory complexes interact with and
shape MERVL-dependent transcription. We present a hypotheti-
cal model incorporating this potential role for REX1. As studies to
determine the role of HERV -driven processes for human ES cells
(HESCs) are ongoing, we will briefly review differences with the
mouse and explain outstanding questions.
Apart from pluripotent cells, several TEs including ERV are
active and expressed in the germline, in pre-implantation embryos,
and in the placenta (21, 22). These are exactly the tissues relatively
devoid of DNA methylation (23), similar to the epigenetic chro-
matin state in many tumors (24), which is also characterized by
widespread DNA hypomethylation. At present, there is little infor-
mation on the potential activity of other repressing mechanisms
toward TE silencing, apart from the main methylation-dependent
mechanism (7). However, we suggest that the epigenetic mech-
anism operative in ES cells described here may carry out such
functions. We hope that a better understanding of the DNA-
binding factors and their interactions with chromatin modifying
regulators may advance future understanding of the relationship
between HERV regulation and tumor prevention. We therefore
point out the activity of similar mechanisms in human cells and
consider their potential relevance for tumor formation and/or
progression.
TRANSPOSABLE ELEMENTS AND ENDOGENOUS
RETROVIRAL ELEMENTS
Transposable elements exist as either DNA transposons that
directly jump from one location to another or as so-called retro-
transposons that use an RNA intermediate (which in turn is
retro-transcribed into DNA before reinsertion into the genome).
Retrotransposons can be further divided into long terminal repeat
(LTR)-containing TEs (LTR retrotransposons and ERV) and non-
LTR retrotransposons LINE and SINE (long and short interspersed
nuclear elements).
Long terminal repeats are generated during the reverse tran-
scription step. LTRs recruit the cellular transcription factors (TFs)
in charge of proviral transcription and produce the 5′ and 3′ ends
of the transcripts (25). In mammals all LTR transposons are related
to ERV, which are considered (defective) descendents of ancient
retroviral infections of the germline.
Animal retroviral diseases (i.e., Jaagsiekte in sheep) were already
described at the turn of the nineteenth century, and particles
derived from ERV were identified in the late 1960s in birds and
mice. Also, in different mammalian species abundant expression
of ERV in placenta and trophoblastic cells had been known since
the 1970s (26–28). Reverse transcriptase (RT) assays and electron
microscopy were used to identify additional ERV particles, and
ERV-reactive antibodies were searched for in sera and other body
fluids. The understanding of ERV was limited however, as nei-
ther the integration of RNA in the genome, nor non-Mendelian
genetics were widely accepted concepts at the time.
Much was learned about ERV in the course of studies on tumor-
producing virus in chicken, especially avian endogenous leukosis
virus (ALV) and the closely related Rous sarcoma virus (RSV),
using a combination of virological and immunological methods
common at the time or developed for this purpose [reviewed by
Weiss (29)]. Neutralizing sera against envelope proteins were avail-
able and serological tests were developed for “group-specific anti-
gen” (GAG) common to serotypes. This allowed the detection of
GAG protein in non-infected animals, suggesting the endogenous
presence of this viral protein. Mendelian transmission of virally
derived characteristics was established in appropriate crosses (i.e.,
between Gag-positive and negative inbred lines). Furthermore,
the use of nucleic acid hybridization allowed for a positive identi-
fication of endogenous copies very similar to virus-derived RNA.
HERV was first discovered in normal brain tissue (30), and similar
to other mammalian species the human placenta was shown to be
permissive to the expression of HERV.
As repeated DNA elements, ERVs were included in the category
of “junk” DNA and long considered not relevant. More detailed
analysis has further been hampered by cross-hybridization among
related elements, and both element-specific probes and amplifica-
tion assays have been scarce for a long time. Extensive sequencing
projects that have delivered complete mouse and human genomes,
have finally provided tools and information to appreciate the
extension and importance to the genome of TE and ERV in
particular (21).
As opposed to exogenous retrovirus, ERVs are an integral com-
ponent of the genome in all cells of an organism (5, 6). Posterior to
integration, re-activation, amplification, and transposition events
have produced defective proviral derivatives of variable integrity
dispersed throughout the genome. In the most extensive cases of
genetic lesion/degeneration only isolated LTRs are left as molecu-
lar fossils of previous integrations. Autonomous ERV encode the
canonical retroviral GAG (capsid and matrix protein), POL (RT;
IN, integrase), and ENV (envelope proteins) (Figure 1). Although
over the years ERVs have mutated and accumulated defects in
the coding regions of some or all of their genes, some still have
open reading frames (ORFs) and thus direct the expression of
(a subset of) these proteins. Dependent on the amount of muta-
tions acquired, autonomous elements can still recruit the necessary
cellular machinery to produce infectious particles, while non-
autonomous variants rely on related elements to do so. Although
TEs are classified based on sequence similarity, each group con-
sists of a range of similar but clearly distinguishable elements.
Furthermore, within each group copy numbers and autonomy
status differs between individual elements (5).
Based on the sequence of their RT genes and their relationship
to described genera of exogenous retroviruses, ERVs are divided
into three families or classes (31): ERVI/class I, ERV-K/class II
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FIGURE 1 | Endogenous retroviral elements (ERVs) result from the
occasional infection of a germline cell by a retrovirus, whose
(potentially) defective offspring is transmitted further as a provirus in
a Mendelian fashion. ERVs typically encode the canonical retroviral
proteins GAG (group-specific antigens; capsid and matrix protein), POL
(RT, reverse transcriptase; IN, integrase), and ENV (envelope). The ERVs
are divided into three classes based on the sequence conservation with
active retrovirus; class I (eMLVs), class II (musD/ETn/IAPs), and class III
(ERV-L). ERVs are flanked by LTRs (green boxes) of 300–1,200 nucleotides
as a result of the retrotransposition event. Class III ERVs make up almost
5% of the mouse genome and consists of muERV-L/MERVL elements
(depicted) and the non-autonomous mammalian apparent LTR
retrotransposons (MaLRs). The muERV-L family members have Gag and
Pol genes but no detectable Env, a dUTPase gene (not shown). For the
lack of ENV they are defective for cell to cell transmission. In addition to
muERV-L, the mouse genome contains many thousands of ERV-L derived
LTR elements termed MT2-Mm. LTRs are bound by transcription factors
(TF) that drive transcription. ERV elements may also bind TF in the body of
their genes, probably influencing chromatin dynamics or surveillance. After
initial insertion (and transposition), ERVs over time may accumulate
mutations and have contributed significantly to the generation of new
transcription factor binding sites and hence impact on gene expression,
genome function, and evolution. Transposon-derived promoters drive
expression of alternative transcripts, including many of the LncRNAs
detected by the ENCODE project, orchestrate stage, and
tissue-dependent transcription, or serve as alternate promoters.
(IAPs and MusD/ETn), and class III (ERV-L/MaLR). Class I ERVs
comprise <1% of the mouse genome and this class is typified
by the well-studied type-C murine leukemia viruses (MuLV), and
also includes eMLVs, VL30, and MuRRS elements. Mouse mam-
mary tumor virus (MMTV) is typical of the class II ERVs, which
also includes IAP, musD, and deleted musD variants called ETn
elements. MusD elements contain Gag-Pro-Pol genes, but lack an
Env gene and vary from 5 to 7 kb in length. ETns are flanked by
LTRs but mainly contain sequences of unknown function.
The Class III ERV in the mouse consists of two types of
retrotransposon elements: murine ERV-L elements (muERV-
L/MERVL) and the mammalian apparent LTR retrotransposons
or MaLRs. After its initial identification in humans (32) the ERV-
L family turned up in all placental mammals. The ERV-L family
members are about 6.5 kbp in length and carry Gag and Pol
but no Env genes, and carry an extra dUTPase gene (Figure 1).
MERVL/MuERV-L (mouse ERV with a leucine tRNA primer bind-
ing site), is present in over 650 full-length copies in the C57BL/6
genome.
In addition, the C57BL/6 genome carries 37,000–38,000 copies
of MERVL-derived LTRs called MT2-Mm. MT2 (MERVL) and
MaLR LTRs share about 50% homology at the DNA level. MaLRs
are very common, non-autonomous LTR elements that occupy
4.8% of the mouse genome. Among the MaLR retrotransposons
three subfamilies are discerned, termed MT (about 2 kb), ORR1
(2.5 kb), and MLT. The non-autonomous but active MaLRs are
all internally deleted, containing only non-coding repetitive DNA
flanked by LTRs.
Elements of active TE/ERV families in the mouse (i.e., IAP and
ETn in the mouse) display high levels of polymorphism, contribut-
ing to genetic variability within species. Elements detected in one
strain (C57BL/6J) are absent in other three strains investigated
(60 and 25% of IAP and of ETn/MusD elements, respectively),
and differences in expression levels or the generation of alternative
transcripts of ERV elements was also observed (33).
The activity of TEs in general and ERV in particular may
contribute to pathogenic processes in different ways (1). Stress
signals resulting from injury, infection, or inflammation may
relieve repression of ERVs, provoking the expression and assem-
bly of infectious virions. Independent of the pathogenicity of the
resulting virions, reintegration may damage the genome (2). De-
repressed ERVs may direct the production of retroviral proteins
that either contribute to cell fusion (34) or display characteristics
as superantigens causing inflammation (3, 35). Altered gene activ-
ity of ERV loci can affect the expression of neighboring cellular
genes (25, 36).
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To avoid deleterious effects of TEs/ERVs activation of any kind,
mammalian cells have acquired a multitude of defense responses.
They act at different stages of the TEs life cycle starting with provi-
ral transcription and processing of resulting RNAs. Other mecha-
nisms interfere with various steps required for productive infection
and integration of retrovirus into the genome: release of particles,
receptor binding, uncoating, deamination (APOBEC enzymes),
and intracellular trafficking (31). In the mouse germline, tran-
scriptional repression of retrotransposons is regulated through
DNA methylation of their regulatory LTR regions (37). This
process is dependent on co-operating small RNAs (piRNAs) and
PIWI-proteins in a mechanism unique to the germline in mam-
mals (38). This review will focus on the role of transposons as
controlling elements of pre-implantation development and stem
cell pluripotency at the level of transcriptional regulation. As there
is no evidence that the PIWI pathway is relevant for these tissues,
it will not be further discussed here.
THE CONTRIBUTION OF TE TO THE EVOLUTION OF
REGULATORY DNA
Endogenous retroviral elements largely lack transcriptional activ-
ity in differentiated cells and tissues as a result of DNA
methylation-dependent silencing (7). However, expression of ERV
families in different species is elevated in the germ cells, in
pre-implantation embryos and also in the placenta (39–42).
Retrotransposons modulate gene expression in these tissues in
different ways [reviewed in Ref. (36), see also Figure 1]. Tran-
scription of retrotransposons may serve as a source of small RNAs
that interfere with gene transcription, or produce long non-coding
RNAs (lncRNAs). A substantial portion of total lncRNA sequence
across species (~30% in human) is TE-derived. Conversely, TEs
contribute to a full two-thirds of mature lncRNA transcripts, as
relative to their absence from protein-coding transcripts (43).
TEs and particularly retrotransposon-derived LTRs profoundly
shape expression of surrounding genomic loci through long dis-
tance enhancer or repressor activities, which may favor the use of
alternative promoters, exons/splice sites, or polyadenylation sites
(25, 36, 44).
It has been argued that the accumulation of TE in the genome
has provided an abundant source of non-functional DNA with
progressive mutations for evolution to act upon. Indeed (degener-
ated) LTR from ERV have been frequently recruited as binding sites
for TFs (45). A well-studied example is the expansion of binding
sites for the TF CTCF (CCCTC-binding factor), a DNA-binding
protein that insulates transcriptional and chromatin domains (46).
Mouse ES cells have thousands of CTCF-binding sites that are not
conserved in the human genome, as they are found in B2 retro-
transposons (47), a rodent-specific SINE, which originates from
accidental retrotransposition of various polymerase III transcripts
(31). Species-specific activation of retroelements has generated
novel species-restricted CTCF-binding sites with active chromatin
insulator function also in other species including rodents, dogs,
and opossum (48).
Similarly, specific families of TE are enriched for TF binding
sites, for example Class II elements for SOX2 and POU5F1 bind-
ing (47). Similar to the extension of CTCF-binding sites, regulatory
elements carried on by transposons contribute to differences in
gene expression patterns between different mammalian species
(49). In line with remarkably restricted and regulated expres-
sion patterns, retrotransposon-directed transcription contributes
to gene regulation in the endometrium (50), and during pre-
implantation development (40). Transposon-derived promoters
synchronize stage-specific gene expression in two-cell embryos
(36, 51) and ERV-derived cis elements have been incorporated in
regulatory networks in pluripotent stem cells (see below).
PRE-IMPLANTATION DEVELOPMENT
After fertilization, the mammalian zygote develops into a multi-
cellular blastocyst, which implants in the uterus for further devel-
opment. Already at the first stage, genome-wide reorganization
takes place to ensure that after protamine/histone exchange and
demethylation of the male genome and the initiation of replication
of haploid genomes, fusion of pronuclei takes place. Large-scale
chromatin reorganization includes but is not limited to epigenetic
modifications that are intertwined with zygotic gene activation
(ZGA). Methylated cytosines are removed from both parental
genomes in early cleavage embryos (23). While the maternal
genome is passively and progressively demethylated during cleav-
age divisions (Figure 2), the paternal genome is actively demethy-
lated in the zygote, at least in the mouse (52). During these early
stages, a distinct chromatin structure and nuclear architecture are
in place concomitant with the absence of structural restrictions to
transcription.
Several excellent reviews detail the progress of cell division fol-
lowed by cellular differentiation steps during pre-implantation
development and the accompanying changes in chromatin states
(15, 53, 54) (see also the legend of Figure 2). The diploid zygotic
genome results from the gradual (55) fusion of paternal and mater-
nal genomes into a totipotent embryo, referring to the ability to
give rise to both embryonic and placental tissues. This property
is maintained during cleavage divisions up to the eight-cell stage.
Afterward, cell specification is initiated, concomitant with a loss
of totipotency, which is definitive at the 32-cell stage.
A next major event is compaction of the loosely connected
cells into a more tightly associated structure, followed by the suc-
cessive generation of morula and blastocyst. Simultaneous with
compaction cell polarization takes place, which initiates a first cell
differentiation, separating cells in the ICM from the surrounding
Trophectoderm. Posteriorly, in the late blastocyst cells in the ICM
separate into epiblast (or primitive ectoderm) and primitive endo-
derm (or hypoblast) in a stochastic process (56). As a result of these
two successive differentiation steps, the late blastocyst contains
three separated cell types or lineages: the trophectoderm, the prim-
itive endoderm, and the epiblast. While the trophectoderm and the
primitive endoderm contribute to extraembryonic tissues, the epi-
blast gives rise to all cell types of the developing embryo proper.
Once these lineages have been specified in the early embryo, they
are separated and become committed to a particular fate.
Formation of the zygote and posterior cleavage divisions are
associated with specific mechanisms of regulation as a result of
specific epigenetic features and the spatial organization of the
newly formed diploid genome (53, 57). These include but are not
limited to differential methylation of histones and DNA, as well as
active DNA demethylation (see below and Figure 2). This period
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FIGURE 2 |Top panel: schematic representation of fertilization, formation
of the zygote, and cleavage divisions, followed by the successive
generation of morula and blastocyst. Transcripts derive from maternal
deposits, or correspond to the two transient waves of de novo transcription:
zygotic gene activation (late zygote-two-cell) or ZGA, and mid pre-implantation
gene activation (MGA). The temporal changes in expression levels of
important chromatin modifiers are indicated. Bottom panel: time course of
genome-wide (de)methylation. By the time of implantation, DNA methylation
is re-established and TE are rapidly silenced. Demethylation is not uniform,
i.e., certain TE (i.e., IAP) and imprinted loci are protected from demethylation.
The diagram also shows a peak of unique expression of muERV-L, Zscan4,
Tcstv3, and others in two-cell embryos.
is associated with specific patterns of gene expression (40, 58,
59) that reconcile these mechanistic features with developmental
requirements.
Among the earliest expressed genes are several MaLR and
muERV-L family transposons (the latter collectively referred to
as MERVL), and chimeric transcripts that initiate on them. In
the mature oocyte/zygote, MaLR-derived sequences are overrepre-
sented in transcripts (17, 40, 60). In two-cell embryos, muERV-L
itself displays a transient increased expression (16) and MERVL
sequences are incorporated into epsilon virus-like particles
observed in the early mouse embryo (61). In addition to MERVL
itself, over 50 transcripts have been identified that are expressed in
two-cell stage embryos and are directly linked to MERVL elements
(17). We will refer to these genes as LTR-linked 2C genes.
By contrast, class II IAP and musD/ETn elements are expressed
from the blastocyst stage onward (62). ERV-driven gene expression
is important at these stages, as at least in the case of LINE1 ele-
ments (L1Md_T class) (63) as well as muERV-L elements (64),
cleavage division is impaired upon targeted depletion by antisense
oligonucleotides.
CELLULAR HETEROGENEITY AND NAIVE PLURIPOTENCY
Mouse ES cells can be derived from the ICM of blastocyst embryos
(12), a stage posterior to ICM and trophectoderm lineage separa-
tion. ES cells share several characteristics with cells in the ICM
of the blastocyst, and can differentiate in vitro into all the cell
types of a fetus (including the germline). ES cells are consid-
ered pluripotent because in chimeric embryos they contribute
to each of the three germ layers of the embryo proper (11).
Only rarely do they contribute to the extraembryonic tissues in
the placenta, providing a distinction with totipotent cells in the
two-cell embryo. ES cells can be maintained in culture for an
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apparent indiscriminate number of cell divisions (a property called
self-renewal).
Maintenance of ES cells in vitro depends on extracellular sig-
naling by LIF and BMP4. Signals converge on the OCT4, NANOG,
and SOX2 TFs, which mutually stimulate each other’s expres-
sion, and repress genes either promoting or associated with cell
differentiation. Together these core pluripotency factors form a
co-operating network of TFs, whose activity also relies on the
recruitment of epigenetic regulators (13, 65, 66). Contrasting with
the uniform expression of OCT4 and SOX2 in all pluripotent
cells of mouse ES cell cultures, heterogeneous expression has been
observed for several genes including Zfp42/Rex1 (67), Nanog (68,
69), Stella (Dppa3/Pgc7 ) (70), Esrrb, Pecam1 (71, 72), and Zscan4
(72, 73). The exact relationship between expression of these vari-
ous markers is unknown. At least in the case of Stella, Pecam1, and
Rex1, expression seems to mark the same cell population (70).
Interestingly, after selection for high expression of such factors,
often a heterogeneous population is reconstituted spontaneously
(67, 70) and cells negative for markers such as NANOG, REX1, or
STELLA can regain expression for each of these factors. Therefore,
cells shuttle between high and low expressing states and the result-
ing heterogeneity reflects the presence of subpopulations of cells,
as opposed to an irreversible differentiation status. The differences
in gene expression levels between subpopulations may also define
distinct self-renewal and differentiation properties, which together
define developmental potency. High expression of those genes
correlates with self-renewal in vitro and enhanced contribution
to chimeric embryos. Cells with low expression show increased
(but reversible) expression of differentiation markers (67, 70,
74), exhibit enhanced sensitivity to differentiation-inducing con-
ditions in vitro (70) and show altered contribution to chimeric
embryos (67).
Different models have been proposed to describe this cellular
heterogeneity. According to a first model, cells transition between
metastable states referred to as “naive” and “primed.” The tran-
sition between different states is determined by differentiation-
inducing ERK signaling, in such a way that inhibition of ERK
signaling drives cells into a more“naive”homogeneous pluripotent
state (75). In addition to compacted morphology, demethyla-
tion of the Oct4 promoter region, silencing of retroviral vectors,
two active X-chromosomes in female cells, LIF dependency and
competency for germline contributions (75), this “naïve” state or
ground state is characterized by homogenous expression of Nanog
and Rex1 (76).
MERVL-DRIVEN TRANSCRIPTION IS SPECIFIC FOR THE
TWO-CELL STAGE
A distinct level of heterogeneity within ES cell cultures is related to
the sporadic and transient transition of mouse ES cells into more
totipotent identities. A subset of cells in a pluripotent cell cul-
ture can be separated from the other cells based on the expression
of a red fluorescent protein driven by the regulatory sequences
from a MERVL-derived LTR element (17). As differences in regu-
lation of MERVL-derived LTRs have already been described (77),
it remains to be established whether expression of all MERVL ele-
ments is equally exclusive. This particular MERVL element directs
gene expression exclusively in two-cell embryos and in a limited
number of cells (in the order of 1%) within ES cell cultures. These
cells (referred to as “2C-like”) express transcripts (see Figure 2)
that can be ascribed to three (overlapping) groups: (1) the MERVL
family of ERV (but not the vast majority of other retrotrans-
posons) and the GAG protein it encodes; (2) their corresponding
LTR promoters and chimeric transcripts with junctions to MERVL
elements; (3) a group of genes previously shown to be restricted to
the two to four-cell stage of development (see Figure 1), includ-
ing Zscan4, Tcstv1/3, Eif1a, Gm4340/Thoc4, Tdpoz1–5, and Zfp352
(73, 78). Over 500 genes transcribed in 2C cells are also active at
the two-cell stage in embryos, including 52 genes that generated
chimeric transcripts linked to MERVL elements (17).
Surprisingly, similar to the absence of pluripotency-associated
TFs OCT4, SOX2, and NANOG from two-cell mouse embryos,
2C-like cells do not express these markers at the protein level (17).
In accordance with its gene expression pattern specific for two-cell
stage embryos, the developmental potential of 2C-like cells is not
restricted to embryonic cell types. In chimeric embryos, 2C-like
cells contribute to the epiblast as expected, but also to extraem-
bryonic tissues such as trophectoderm, the yolk sac, and placenta
(17). Hence, muERV-L regulatory sequences are necessary and
sufficient to drive expression in rare ES cells that express MERVL,
and display enhanced developmental potential.
CHROMATIN STRUCTURE: DNA AND HISTONE
MODIFICATIONS
As opposed to genetic alterations to the genome, epigenetic mech-
anisms are those mechanisms that control gene expression without
changing the underlying DNA sequence. Such mechanisms involve
remodeling of the chromatin structure as a result of the formation
of functional or 3D domains, or posttranscriptional processing
in the form of DNA (de)methylation and histone modifica-
tions. A score of non-coding RNAs including microRNA, lncRNA,
and piRNA also contribute to epigenetic regulation. Modifying
enzymes such as DNA (DNMT) and histone methyltransferases
(HMTs) are recruited by DNA-binding factors or through affin-
ity for relevant modifications in chromatin (79). Combined, these
mechanisms impact on the activity of DNA polymerase and con-
figure the transcriptional landscape of a given genetic locus in a
cell type-specific context.
A first major epigenetic pathway is the presence of methylated
cytosine (normally in CpG nucleotides) in DNA (80). Methyla-
tion at gene promoters usually correlates with repression. DNA
methylation is reversible, either by deamination and base excision
repair or by TET family proteins that catalyze the conversion of 5-
methylcytosine to 5-hydroxymethylcytosine, which in subsequent
steps can be removed from the DNA strand (81, 82). It follows that
the default role of TET1 is related to transcriptional activity (83).
A second silencing mechanism alters chromatin structure
through modifications of histone tails, which are laid down by spe-
cialized enzymes that form part of histone modification complexes
such as HMTs, histone deacetylases (HDACs), or lysine-specific
demethylases (KDMs). The modifier activities can either stimu-
late or repress gene expression, depending on the affected histone
residue and the overall epigenetic landscape of the locus. Notwith-
standing, specific modifications are generally associated with a
defined activity status. The trimethylation of histone 3 at lysine
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4 (H3K4) is associated with active loci. Well-known modifica-
tions associated with repression are the trimethylation of histone
3 at K27 (involved in Polycomb-mediated repression, see below)
and methylation of histone 3 at lysine 9 (H3K9), imparted by
SETDB1/ESET, G9a, and the KMT1A and KMT1B products of the
Suv39h1/2 genes (84, 85).
HDAC1 belongs to the Class I HDAC, nuclear proteins with
activity toward core histones (86). HDACs provide the catalytic
entity for different multisubunit complexes (including SIN3A,
NuRD, CoREST, and NODE). These complexes usually contribute
to transcription silencing in cooperation with other chromatin
modifiers, such as KDMs. A well-studied KDM is LSD1/KDM1A,
which favorite substrate is mono- or di-methyl K4 in H3 (87). The
activity of LSD1 can either stimulate or repress the locus affected.
LSD1-mediated demethylation of H3K9 facilitates activation by
androgen and estrogen receptors (88). By contrast, LSD1 represses
as a subunit of HDAC1/2-containing CoREST complexes (89).
The interplay between the roles of DNA and histone modify-
ing enzymes is an area of active research. Epigenetic marks and
regulators are generally correlated with activity states, but do not
determine them. As a generic model, loci are marked in a mutually
exclusive way with H3K4 (active), as opposed to DNA methy-
lation (inactive). Moreover, several instances have been described
in which H3K9 trimethylation (H3K9me3)-associated silencing of
Class II ERVs in ES cells, is required for posterior DNA methylation
(90, 91).
REGULATION OF ERV BY METHYLATION
DNA methylation is widely recognized as an important epige-
netic mark in silencing of TE and ERV (7) in line with a heavy
presence of methylated CpG within repeated DNA (38). In mice,
deficient in genes encoding proteins involved directly or indirectly
in DNA methylation, particular TE/ERVs are de-repressed, usu-
ally leading to reduced viability and fertility (92). It has become
clear however, that this mechanism does not explain the dynamics
of expression/silencing in undermethylated tissues such as germ
cells, pre-implantation embryos, and stem cells. As an example,
although differential methylation during pre-implantation devel-
opment coincides with expression of LINE1 (93) and IAP elements
(94), as well as ICR regions in imprinted genes [reviewed in Ref.
(95)], transient expression of muERV-L in two-cell embryos is not
related to DNA methylation levels.
During mammalian pre-implantation development, DNA
methylation is highly dynamic (23, 83). Until recently, it was
believed that 5-methylcytosine is removed from the paternal
genome immediately upon fertilization, while this occurs more
slowly and passively afterward on the maternal genome, reaching
a minimum at the blastocyst stage [Ref. (23), see Figure 2]. A
more recent genome-wide analysis (96) has revealed that general
hypermethylation of specific families of LINE1 and ERV retroele-
ments in the sperm is rapidly removed in the zygote. Generally,
retrotransposons maintain this low level of 5-methylcytosine up
to the ICM stage, and do not increase to somatic levels until
later (E6.5/7.5). Thus, repeat elements are undermethylated during
pre-implantation stages. As an exception to this rule, high methy-
lation levels of IAPs are retained throughout cleavage divisions
(94, 96–98).
While enzymatic activity of DNMT1 and DNMT3A/B is essen-
tial for mouse embryonic development, ES cells deficient for all
three genes (TKO cells) mostly retain characteristics of undiffer-
entiated ES cells (99). Surprisingly, expression of ERV is hardly
affected in TKO cells (100). While a few Class I and II ERVs depend
on DNMT-mediated repression, ERVIII is totally unresponsive to
TKO (100, 101).
SILENCING OFMERVL BY RYBP AND ASSOCIATED
POLYCOMB COMPLEXES
In mouse ES cells retrotransposon silencing requires the activ-
ity of among others Eset or G9A-mediated histone modifica-
tion machineries, and polycomb repressive complexes (PRC).
Polycomb group (PcG) proteins are chromatin modifiers with
important functions in cell proliferation, axial development, and
X-chromosome inactivation (XCI) (102). In addition, PcG pro-
teins contribute to pluripotency of mouse ES cells and coordinate
genetic programs that orchaestrate differentiation of stem cells and
cell fate decisions (103). PcG form two main multiprotein com-
plexes termed PRC2 and PRC1 (104). These complexes bring about
chromatin and histone modifications and catalyze the trimethyla-
tion of histone H3 at lysine 27 (H3K27me3) and the monoubiq-
uitination of lysine 119 on histone H2A (H2AK119Ub1) for
PRC2 and PRC1, respectively. A standard model postulates that
chromatin-tethered PRC2 modifies histone H3, the resulting
H3K27me3 is bound by the CBX component of PRC1, which in
turn deposits H2AK119Ub1 (104). The concerted and sequen-
tial activities of PRC2 and PRC1 generate an inhibitory chro-
matin environment, limiting transcription of nearby genes (see
Figure 3).
RYBP was identified as a protein that interacts with both RING1
and Yin Yang 1 (YY1) (105). RYBP is a zinc finger protein, which
in addition to its association with PcG complexes through RING1
is also a subunit of complexes containing the OCT4/POU5F1 TF
essential for pluripotency in ES cells (106, 107). Despite its interac-
tion with Ring1B, genome-wide chromatin binding of RYBP does
not overlap well with PRC1 binding (108).
In addition to recruitment of PRC1 via interaction with PRC2
as outlined above, PcG complexes distinct from PRC1 are also
recruited to a subset of CpG islands (CGIs) not marked by
H3K27Me3 (109). CGIs lack DNA methylation and are associ-
ated with most mammalian gene promoters (110). Variant PRC1-
related complexes that bind CGIs contain RYBP, and also KDM2B
(FBXL10), which specifically recognizes non-methylated DNA in
CGIs. KDM2B in turn recruits PRC1, leading to monoubiquityla-
tion of H2AK119 and repression of associated genes. Yet another
variant PRC1 complex also contains both RING1B and RYBP in
addition to MEL18 (111) and differs from the canonical PRC1 in
that the CBX7 subunit is excluded. The presence of CBX7 in these
complexes appears to be mutually exclusive with association of the
RYBP subunit (see also Figure 3).
Constitutive depletion of Rybp in a mouse model causes lethal
gastrulation defects and obviates the generation of ES cell lines
(112). By contrast, conditional inactivation of Rybp allows for the
generation of ES cells with apparent normal expression of stem cell
markers (108). Although RYBP associates with a subset of H3K27
and H2K119Ub-modified PRC1 target genes, it contributes only
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FIGURE 3 | RYBP and distinct PRC1-like complexes. Polycomb Group
genes (PcG) assemble into multiprotein complexes and, depending on the
subunit composition, the complexes are recruited to different types of
target sites. PRC1 (Polycomb repressive complex 1) is a canonical complex
composed of either RING1A/or RING1B, MPH1/2/3, CBX2/7/8, and one of
the Polycomb group RING fingers proteins (PCGF2–5) and is referred to
here as CBX-PRC1 (A). CBX-PRC1 mediates H3K27me3-dependent
silencing of bivalent promoters. PcG-regulated promoters devoid of
H3K27me3 recruit a RYBP-containing variant complex termed RYBP-PRC1,
which appears similar to a KDM2B-containing complex that recognizes
non-methylated CpG islands (A). For clarity, only the subunits that differ
between CBX-PRC1 and RYBP-PRC1 are shown, in addition to RING1B.
RYBP silences the expression of transposable elements, including
MERVL. RYBP can interact with both REX1 and/or RING1B. In this
hypothetical model, REX1 might tether RYBP and the polycomb silencing
complex to specific binding sites in MERVL or MERVL-derived control
elements (B). Repression of class I and class II ERVs (C) is dependent on
SETDB1 histone H3 lysine 9 trimethylase activity (H3K9me3). SETDB1 is
believed to be recruited to its ERV targets via KRAB-containing zinc finger
proteins and their co-repressor KAP1. MERVL repression is dependent on
the presence of H3K9Me2 deposited through the combined action of
G9a/GLP (D). Surprisingly, deletion of a variety of other chromatin proteins
including LSD1, RYBP, and KAP1 also derepresses MERVL. The interplay
between these pathways is presently unknown. LSD1/KAP1 and RYBP
might all be recruited trough YY1-family DNA-binding factors as YY1
independently interacts with either KAP1 or RYBP (D).
moderately to repression of these PRC1-regulated promoters and
is dispensable for the association of PRC1 components MEL18
and RING1B to those targets (108). By contrast, in ES cells RYBP
is necessary for repression of MERVL (but not musD and IAP)
and two-cell stage-specific genes (see below). No direct evidence
has yet implicated RING1B/PcG as a necessary cofactor in the
observed regulation of MERVL levels by RYBP. However, in a lim-
ited analysis of mouse ES cells deficient in both RING1B and PRC2
(113), IAP, and RLTR33 (and to a lesser extent ORR1A1, RLTR4,
and MMVL30) were upregulated, pointing toward a generic role
for PcG in regulation of TE.
REGULATION OFMERVL BY YY1-FAMILY MEMBERS
Among the genes showing non-uniform expression in ES cell
cultures is Rex1/Zfp42, a zinc finger protein with a unique expres-
sion pattern in ES cells (114, 115). Modest levels of expression
are also detected during spermatogenesis and early trophecto-
derm derivatives and placenta in the mouse (114, 116). Rex1
is expressed throughout pre-implantation mouse development
(117). Although deficiency of Rex1/Zfp42 affects ES cells only
weakly (20, 115) expression is frequently used to identify pluripo-
tent stem cells (118). REX1 has an essential role in the initiation of
XCI in female ES cells (19), through regulation of the lncRNA
Tsix (18). Although depletion of Rex1 does not affect expres-
sion levels of pluripotency markers (except for Tsix), it allows for
upregulation of MERVL expression (20). REX1 has been shown
to bind to MERVL loci in in vivo chromatin binding assays. Reg-
ulation of MERVL by REX1 is even more pronounced in vivo,
as transient gain-and-loss of REX1 both influence MERVL levels
during the late cleavage stages of the embryo, in a way compatible
with a silencing function for REX1 (20). Thus, REX1 contributes
to silencing of ERV expression in mouse ES cells and during
pre-implantation development.
REX1 shares high homology in the DNA-binding zinc fin-
gers with the well-studied, ubiquitously expressed TF YY1. YY1
is the prototype of a small family of DNA-binding TFs that also
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includes YY2 (119). Dependent on the epigenetic environment
and numerous interactions with histone modifying complexes,
YY1 can function as an activator, repressor, or initiator of gene
transcription. YY1 contributes to the control of imprinted genes
(120) and genes encoding regulators of the cell cycle (121), espe-
cially cytokinesis. Intriguingly, YY1 has been described already in
the early 90s as a factor bound upstream of IAP and MMLV ele-
ments (122, 123). In addition, silencing of MMLV in embryonic
cells is also dependent on YY1 (91). In line with the high homol-
ogy in the DNA-binding zinc fingers between REX1, YY1, and YY2
(119), the latter two also bind both IAP and muERV-L elements,
and weakly to musD in ES cells [Ref. (20); Raquel Pérez-Palacios,
Pedro Muniesa, and Jon Schoorlemmer, manuscript in prepara-
tion]. In contrast to more efficient binding of REX1 in ES cells to
muERV-L, YY1 and YY2 preferred IAP (20).
Consistent with in vivo chromatin binding, YY1-family pro-
teins also play a role in regulation of a distinct subset of ERVs.
While selected ERV class I and II elements are silenced by YY1
(in F9 EC cells), class III elements including muERV-L are not
(91). Repression of IAP is also dependent on KAP1 in mouse
ES cells and in early embryos (124). As KAP1 binding to IAP
LTRs is lost in YY1 KD cells (91), and YY1 directly interacts with
both KAP1 (91) and RYBP (105), YY1 may bridge RYBP/PRC1
and KAP1-dependent silencing (Figure 3). By contrast, REX1 (in
mouse ES cells) contributes to silencing of muERV-L and musD
(Class II) to a minor degree (20). Combined, these results are com-
patible with an important role for YY1-family members in ERV
silencing.
Although RYBP interacts in vitro with YY1 (105) as well as
with the related YY2 and REX1 proteins (125), neither of these
proteins form part of RYBP-containing PcG complexes (111). As
YY1-binding sites in ES do not significantly overlap with PRC1 nor
with PRC2 binding (126), it was postulated that YY1 is unlikely
to be relevant for PcG-dependent gene regulation (111, 127).
However, this conclusion was reached ensuing the analysis of
canonical protein-encoding target genes. In view of the data show-
ing muERV-L deregulation in Rybp-deficient ES cells, we suggest
that REX1 (and/or YY1 and YY2) may recruit RYBP and associ-
ated PcG/PRC1 complexes to binding sites in retroviral elements,
ultimately contributing to silencing. This hypothetical model is
depicted in Figure 3.
DIFFERENT ERV CLASSES ARE REGULATED BY DISTINCT
EPIGENETIC MECHANISMS IN MOUSE ES CELLS
Histone H3 lysine 9 methylation (H3K9me2/3) was initially
observed as modification associated with centromeric repeat DNA
and therefore presumed to be involved in repression (128, 129).
It was subsequently observed that silencing of the promoter of
the Oct4/Pou5f1 gene during differentiation is associated with the
presence of H3K9me3 (130). In ES cells, different ERVs also carry
this mark.
In accordance with H3K9me3 and H4K20me3 marking of
ERVs specifically in ES cells (131), a role for SETDB1 in regula-
tion was postulated. Indeed, a wide variety of Class I and II ERVs
including ERVK10C and other IAP elements, musD, and ETn ele-
ments have lost the H3K9me3 mark and are ectopically expressed
in Setbd1-deficient cells (100, 101). SETDB1 (also known as ESET)
is recruited to chromatin through interactions with the KAP1
co-repressor (132). KRAB-associated protein 1 (KAP1) is a co-
repressor of transcriptional repressors of the Zinc Finger Protein
with Krüppel-Associated Box (KRAB-ZFP) family (133).
KRAB-associated protein 1 (also known as TRIM28 or TIF1β)
recruits HDAC and histone methyltransferase machinery to its
chromatin targets. Kap1 deficiency causes developmental arrest
shortly after implantation and gastrulation failure (134). Kap1
cooperates with Cnot3, c-Myc, and Zfx in functions essential for
the maintenance of pluripotency and self-renewal of ES cells (107,
135). Following up on initial reports that KAP1 mediates silencing
of an exogenous virus in ES cells (136, 137), it was subsequently
discovered that KAP1 is essential for repression of a large set
of endogenous retroelements (100, 124). KAP1/SETDB1 com-
plexes are tethered in turn to TE targets through interactions with
KRAB-ZFP.
The genomes of higher vertebrates (including mice and
humans) encode a large group of over 300 TFs named KRAB-
containing zinc finger proteins (138). They contain a varying
number of C2H2 zinc fingers (ZF) that bind DNA in a sequence-
specific way and an N-terminal Krüppel-associated box (KRAB)
domain with transcriptional repression activity (133). As the
KRAB domain associates with KAP1, it was proposed that the
sequence-specific docking of KRAB-ZFPs at given genomic loci
can induce transcriptional repression mediated by KAP1 and asso-
ciated proteins (139). This silencing mechanism is important in
ES cells and operates during preimplantation development (90), in
accordance with high expression of Kap1 at this stage (Figure 2).
More recent results indicate that different classes of ERV are
regulated by distinct chromatin-modification pathways. Class III
muERV-L/MERVL and MaLR (i.e., ORR1A3) families are gen-
erally devoid of the H3K9me3 mark in ES cells (101, 131). By
contrast, MERVL elements carry the H3K9me2 mark, and de-
repression is associated with loss of H3K9me2 (77). Moreover,
while repression of both ERV I and ERV II elements in ES cells is
dependent on SETDB1, this is hardly the case for ERV III (60, 100,
101). MERVL silencing is dependent on chromatin association and
HMTase activity of both G9a (EHMT2) and GLP (EuHMTase1),
two closely related HKMT that form a heteromeric complex
in vivo (60). The complex represents the main HKMTs to cat-
alyze H3K9me1 and H3K9me2 in euchromatin. Deletion of either
G9a or GLP in ES cells dramatically reduces overall H3K9me1
and H3K9me2 levels (140, 141). The mechanisms underlying G9a
recruitment to genomic targets including MERVL are not under-
stood. G9A/GLP does not interact with either KAP1 or KRAB-ZFP
(142). This observation is consistent with the notion that a wave of
MERVL expansion has taken place in the mouse relatively recently
(32), potentially precluding KRAB-ZFP adaptation to these novel
sites. Recruitment mechanisms may rely on other chromatin pro-
teins that reportedly interact with G9A/GLP, including Blimp1,
ZNF200, HP1, and DNMT1 (142).
However, class III including MERVL ERVs are also upregu-
lated in ES cells following Kap1 depletion (124). Silencing relies
on targeting through the 5′UTR/LTR (124). MERVL expres-
sion is also de-repressed in ES cells that lack LSD1/KDM1
(87), a mono- and di-methyl lysine-specific histone demethy-
lase 1 (77). Consistent with the detection of histone modification
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changes in Lsd1-mutant ES cells that are incompatible with LSD1
specificity, additional modifiers copurify with LSD1 complexes
including KAP1-associated HDAC. HDAC acts in concert with
LSD1 to properly repress muERV-L/MERVL in pluripotent stem
cells (77, 143).
MERVL repression is dependent on the presence of H3K9Me2
deposited through the combined action of G9a/GLP (60) and
LSD1/HDAC1 activity, although the interplay between these two
pathways is presently unknown. Furthermore, although RYBP is
not a component of LSD1 complexes (77), this PcG-associated
protein also plays a role (see Figures 3B,D). As outlined above,
RYBP may contribute through association with either REX1 or
YY1. The former may attract demethylating activity through its
interaction with LSD1 (20), while YY1 was shown in turn to
selectively bind KAP1 in undifferentiated stem cells (91), pro-
viding a potential docking site for KAP1 and its associated
activities.
The variety of potentially independent mechanisms contribut-
ing to MERVL silencing could be explained by two different but
not mutually exclusive arguments. First of all, different copies of
MERVL may be regulated by distinct mechanisms. The mouse
genome contains 500–600 full-length and nearly 350 protein-
coding MERVL elements (60, 61). Except the LSD1-deficiency,
which affects many different copies (77), in most studies describ-
ing de-repression of MERVL the difference between induction of
multiple copies versus several fold induction of a few copies has not
been addressed. Alternatively, different mechanisms may be initi-
ated at different time-points of the life cycle, which is discussed
below.
THE CONTRIBUTION OF RETROTRANSPOSONS TO GENE
EXPRESSION SPECIFIC FOR TOTIPOTENCY AND
PLURIPOTENCY
In contrast to silencing of retrotransposons in differentiated cells
and tissues, activity of retrotransposons in the germline and/or
in pluripotent cells destined for the next generation is a crucial
prerequisite to ensure genetic propagation. In line with the result-
ing restricted and regulated expression patterns, retrotransposon-
derived control elements underlie transcriptional networks in
pluripotent stem cells. The binding regions for several core
pluripotency factors including SOX2, NANOG, and POU5F1 show
meaningful overlap with degenerated TEs, i.e., ERV-derived LTRs.
In particular, remnants of class II elements (IAP and ETn) overlap
binding sites for SOX2/NANOG/OCT4 in the mouse (49, 144).
Despite evolutionary innovation and diversification at the level
of individual binding sites, overlap with retrotransposons is evi-
dent in both mouse and human (49). Hence, ERV-contributed
cis-binding sites may underlie the coordination of gene expres-
sion in pluripotent cells in a species-specific manner. The preva-
lence of MERVL-derived control elements and LTRs (Class III
ERV elements) in the vicinity of two-cell stage gene promoters
(17, 60), suggests that they orchestrate coordinated regulation of
gene expression at this stage. The contribution of ERV-derived
sequences to cis-acting regulatory elements is not restricted to
mammals (47, 48, 144). A chicken retroviral (Ens-1) LTR con-
tributes to both the transcriptional networks in ES cells and to
extraembryonic transcription (145).
In placental mammals (Eutherians), female cells silence one
of their X-chromosomes in a process called XCI to accom-
plish equal expression levels of X-encoded genes compared with
males (146, 147). In the mouse, the activity of both X chro-
mosomes is re-established in pluripotent cells in the ICM. This
process calls for the expression of the lncRNA Tsix. The activ-
ity of both X-chromosomes in female ES cell lines is similarly
dependent on Tsix, which counteracts painting of one of the
X-chromosomes by Xist. The level of Tsix RNA depends, in addi-
tion to the promoter, on a cis-acting element called DxPas34
(148). In rodents DxPas34 contains binding motifs for several
TFs including CTCF and REX1 [Ref. (18); Guallar et al. sub-
mitted] and DxPas34 activity is dependent on the presence of
REX1 (in addition to c-MYC and KLF4) (18). Surprisingly enough,
the DxPas34 element has the structure of a repeat element very
similar at the sequence level to ERVs (149). In fact, it is most
similar to, and can be considered a fossilized version of muERV-
L/MERVL. The activity of this element seems unrelated to LTR-
originated promoter activity, as the sequence similarity is in the
internal portion of the retroviral element, and not in the LTRs.
Although XCI is a female-associated process (while most com-
monly used mouse ES lines are male), re-activation of both
X-chromosomes is a hallmark of pluripotency. Naive female ES
cells invariably express Tsix resulting in the presence of two
active X chromosomes. This observation suggests that MERVL-
related sequence elements direct gene expression required for naive
pluripotency (75).
Several genes identified initially as transcripts expressed exclu-
sively in two-cell stage embryos represent transcripts that initi-
ate in MERVL/MT2 LTRs. These include Zscan4, Tcstv1/3, Eif1a
(Gm2022), similar to Tho4, Tdpoz1–5, and Zfp352 (16, 61, 64, 78,
150). We will refer to these genes as LTR-linked 2C genes. ES cells
devoid of individual MERVL regulators discussed above all suffer
de-repression of both MERVL and (a subset of) LTR-linked 2C
genes. This holds in addition to LSD1 for G9A (60), KAP1 (101),
HDAC1 (77), and RYBP (108). Although de-repression of muERV-
L might be a consequence of ectopic expression of LTR-linked 2C
genes, no direct evidence for such a mechanism is available. There-
fore, we favor the hypothesis that aberrant transcription of 2C
genes results from sharing the silencing machinery with MERVL.
In line with this hypothesis, MERVL-positive ES cells are believed
to represent a transient two-cell state accompanied by induction
of LTR-linked 2C genes.
DEVELOPMENTAL POTENCY AND DEVELOPMENTAL TIMING
In contrast to the well-established exclusive contribution of ES
cells to the ICM of the blastocyst of chimeras (and embryonic
tissues during later development), 2C-like cells also contribute
to the trophectoderm and to the yolk sac and placenta in later
embryos. The proportion of 2C-like cells within an ES cell culture
is controlled by LSD1, and to a lesser extent by LSD1-associated
HDAC1 (17). Without LSD1/HDAC1 activity, more cells reside
in the 2C-like state. Not surprisingly then, Lsd1-deficient ES cells
also show enhanced lineage potential in mouse chimera assays
and contribute to embryonic tissues and primordial germ cells, the
amnion, yolk sac, and placental tissues, including giant trophoblast
cells. Therefore, the separation between trophectodermal and
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embryonic lineages established in post cleavage-stage embryos is
overturned in 2C-like cells, which transiently exhibit an expanded
cell fate relative to pluripotent cells. In ES cells RYBP is necessary
for repression of germline-specific genes, as well as for repression
of MERVL class ERVs (not musD norIAP) and two-cell stage-
specific genes (including Tcstv3, Zscan4, Zfp352, and Ubtfl1). In
addition, the collection of genes controlled by RYBP overlapped
very well with LSD1 target genes (77, 108), including a set of
extraembryonic endoderm markers. This coincidence reinforces
the hypothetical model presented (in Figure 3) suggesting that
RYBP and LSD1 act in concert.
Neither self-renewal properties, nor pluripotency (measured
in vitro or by contribution to chimeric embryos) have been rig-
orously established so far for the majority of ES cells devoid of
individual MERVL regulators discussed above (except for Lsd1 and
Rybp). However, available data are compatible with the notion
that deficiency in these MERVL regulators causes defects dur-
ing differentiation (100, 151), which can be interpreted as altered
pluripotency. It is not clear at present whether the shared de-
repression of MERVL in these cells drives a higher percentage
of cells into a 2C-like state which in turn allows differentia-
tion into extraembryonic lineages. Alternatively, de-repression
of MERVL and 2C-stage-specific transcripts initiating on ERV
may be indicative of transcriptional deregulation, allowing for
enhanced plasticity of cell fate and increased extraembryonic
differentiation.
The absence of REX1 in mouse ES cells is accompanied by a
(relatively minor) de-repression of MERVL, suggesting that REX1
may control only few copies among the MERVL elements (20).
It is unclear at present whether this induction reflects increased
MERVL expression in a constant number of expressing cells, or
results from an increased subpopulation of 2C-like cells. In the
latter case, REX1 may negatively influence transition into the 2C-
like state, or stimulate reversal into pluripotent cells (Figure 4).
The latter would be in accordance with its repressing function on
MERVL after its peak expression in two-cell embryos (20). REX1
may regulate this transition indirectly through its interaction with
LSD1 (20), or directly as a transcriptional repressor in concert
with RYBP (125). A final alternative resides in a distinct function
of REX1 in protecting a regulatory ERV locus from generic TE
silencing mechanisms. The above considerations imply that REX1
is present in 2C-like ES cells based on the comparison with two-cell
embryos. In support of this view, Rex1 mRNA levels were not iden-
tified as differentially regulated between 2C-like and pluripotent
ES cells (17). REX1 is subject to RNF12-mediated ubiquitination
and subsequent degradation in pluripotent cells (19). It remains
possible that a similar mechanism lowers REX1 protein levels in
2C-like cells.
A potential enhanced contribution of Rex1-deficient cells to
extraembryonic tissues in chimeras has not been rigorously tested
[see Ref. (115)]. The influence of Rex1 on developmental potency
in vitro concerns some extraembryonic endoderm markers, but is
much more restricted than reported for Lsd1 and Rybp. A role for
Rex1 in MERVL-driven totipotency is not easily reconciled with
the reported differentiation characteristics of Rex1-deficient ES
cells in vitro (115), potentially due to the separate role of Rex1 in
naive pluripotency (Figure 4).
Based on the different requirements for RYBP during the gen-
eration of ES cells from blastocyst versus depletion after lines have
been established, it has been suggested that Rybp is required for
the generation, but not for the maintenance of the ES cells state
(108). This notion coincides with the magnitude of MERVL reg-
ulation by Rex1 during these stages. It is therefore a possibility
that REX1 attracts a repressing complex to MERVL during pre-
implantation development via its interaction with RYBP, while
repression at later stages (including in the ICM/ES cells) is exerted
in conjunction with parallel pathways.
Compared to two-cell embryos, an increase in H3K9me2
methylation at heterochromatin has been reported at the four-cell
stage (152), with the increased level maintained up to the blas-
tocyst stage. A similar increase associated with MERVL elements
may underlie G9A-mediated repression of MERVL after transient
expression in two-cell embryos.
Zscan4, PLURIPOTENCY, AND TWO-CELL EMBRYOS
An alternative pathway conferring characteristics of two-cell
embryos on ES cells implicates the Zscan4 locus. Zscan4 is the
common name for several transcripts generated from a cluster
of six paralogous genes with high homology (73). ZSCAN4 is
a nuclear protein with DNA-binding Zinc Fingers and a SCAN
domain for protein–protein interactions. In a pattern reminiscent
of MERVL, Zscan4 is expressed exclusively in two-cell embryos
and transiently and reversibly in only a small percentage of ES
cells in culture (73, 153). Zscan4-expressing cells selected to near
homogeneity (using a reporter gene inserted in the locus) do
exhibit standard pluripotency characteristics such as expression
of OCT4/POU5F1, in vitro differentiation into three germ layers
and contribution to chimeric embryos. Despite the relatively small
percentage of Zscan4-expressing cells in an ES culture at a given
time point, all cells cycle through a Zscan+ state over a span of
9–10 passages. Failure to do so results in cell death associated with
telomerase-independent telomere shortening, loss of normal kary-
otype, and genomic instability. These observations are consistent
with a role for ZSCAN4 in the lengthening of telomeres through a
recombination process unique to one- and two-cell embryos called
sister-chromatid exchange (154).
At this moment, there is no direct proof that implicates
ZSCAN4 in regulation of either MERVL-driven transcription or
MERVL-directed passage to the 2C-like state (17). They seem to
be coregulated as Zscan4 is manifold induced in 2C-like cells,
depletion of 2C-like cells also depleted Zscan4 levels (17), and
both Zscan4 and MERVL are upregulated in KAP1- and LSD1-
deficient ES cells, and to a minor extent in G9A deficient cells.
Hence, ZSCAN4 might directly regulate MERVL-driven conver-
sion to 2C, and/or MERVL may somehow coordinate induction of
genes required for SCE. Integration of both processes might rely
on REX1, which has been shown to regulate expression of MERVL
in both early mouse embryos and ES cells (20), and Zscan4 in
embryos (117). A difference between regulation of Zscan4 and
MERVL expression is the dependence of Zscan4 levels on the pres-
ence of REX1 in two-cell stage embryos (117). By contrast, MERVL
expression is indifferent to REX1 levels at this stage (20), suggesting
a potential mechanism underlying the differences between Zscan4-
and MERVL-expressing ES populations.
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FIGURE 4 |Top panel: schematic representation of relevant stages
during mouse pre-implantation development. A specific set of genes
transiently expressed at the two-cell mouse embryo (see also Figure 2),
contributes to the totipotent status distinctive of those early stages. See
text for further information. Middle panel: transient subpopulations of
mouse ES cells. MERVL-derived elements drive the expression of genes
specific to two-cell embryos in a transient subset of ES cells, discriminating
pluripotent ES cells with ICM characteristics from totipotent 2C-like cells
with expanded developmental potential. Independently, self-renewing
(OCT4/SOX2 positive) ES cells shuttle between a so-called naive pluripotent
status of gene expression and a primed state, characterized by the ability of
the former to contribute to germline chimeras. These populations can be
separated based on the expression of various heterogeneously expressed
genes including Rex1. Among other characteristics of naivety, figures high
expression of Rex1 in all cells, as opposed to heterogeneous or low
expression. Primed cells exhibit a lower potency of development and no
expression of Rex1. These populations bear similarity to ICM cells in the
blastocyst and Epiblast Stem cells (EpiSC), respectively. REX1 contributes to
regulation of MERVL-derived transcriptional control elements relevant to
these cellular transitions. REX1 is present throughout pre-implantation
development (Figure 2) and regulates MERVL and Zscan4 expression at
these stages. Therefore a function of REX1 in the transition between
totipotent 2C-like and pluripotent ES cells is speculated on (see text). Levels
of Zfp42 are not significantly affected in 2C-like cells (17). On the other
hand, REX1 positively affects re-activation of the inactive X-chromosome
typical of the ICM and naive ES cells, by promoting the transcription of Tsix.
Bottom panel: LTR regulation. The LTR drives expression of MERVL and
totipotency-specific gene expression in 2C-like cells with totipotent
characteristics, which co-exist in culture with pluripotent REX1-expressing
ES cells. REX1 silences MERVL in ES cells, and is necessary for full
expression ofTsix.Tsix expression in turn is instrumental in both the
re-activation of the paternal X-chromosome in the blastocyst, which is
silenced at earlier stages and maintenance of re-activation compatible with
naive pluripotency. In primed ES cells and in EpiSCTsix is silenced and XCI
is installed. LS-TFs, lineage specific transcription factors expressed in
primed ES cells and EpiSC; Xp, paternally derived X-chromosome XCI;
X-chromosome inactivation; Tsix, lncRNA counteracting XCI, whose
transcription is driven by a MERVL-related repeat sequence.
HUMAN ERV AND EMBRYONIC STEM CELLS
The contributions of MERVL to gene expression restricted to dif-
ferent states of developmental potency, and its epigenetic control
mechanisms (Figures 3 and 4) have been described in mouse
stem cells. Studies to determine the role of similar HERV -driven
processes for HESCs are ongoing. We will briefly discuss present
knowledge and issues being addressed in this respect. Definitely,
many differences exist between HESC and mouse ES cells (155).
Although pluripotent, the differentiation properties and growth
factor dependency of HESC are more similar to mouse Epiblast
Stem Cells [reviewed in Ref. (14)]. If remnants of MERVL-related
sequences are present in human they are much more degenerated
(156). Whether human MERVL-related sequences that influence
TSIX expression and XCI in HESC exist, is an unresolved issue at
present (157, 158). Surprisingly, few data are available regarding
the expression of HERV in human tissue in general. In HESC,
HERV-K expression is very high (159). As opposed to a wide vari-
ety of differentiated cells, this element is marked in HESC with
the activity associated H3K4Me3 modification. Moreover, bind-
ing sites for the core pluripotency factors NANOG, OCT4, and
SOX2 are located within HERV-K LTRs. HERV-K(HML-2) RNA
and protein are both expressed in undifferentiated HESCs (160).
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As exemplified by rapid silencing upon differentiation, HERV-
K expression is representative of the pluripotent state of HESC
(159, 160), potentially displaying regulation similar to MERVL
in the mouse. HERV hardly displays retrotransposition activity, as
opposed to rodent ERVs. However, present inactivity does not rule
out its previous recruitment as cis-control element. Considering
the dearth of information on gene expression in human embryos
and placenta (161, 162), HERV expression may be more promi-
nent than presently known. By contrast, as a result of expanded life
span, human cells are equipped with a more extended set of anti-
tumor mechanisms compared to rodents. It cannot be excluded
that expanded life span also has required a tighter control of TEs,
which has evolved differently from rodents.
Moreover, the muERV-L/MERVL regulator REX1 is a well-
defined marker for both mouse and HESCs (163, 164). REX1
expression also defines heterogeneity within OCT4 and TRA-1-60
positive populations of HESCs (164). Low or absent REX1 expres-
sion identifies an OCT4 positive cell type that does not revert back
to REX1 positivity under normal conditions and is prone to dif-
ferentiation into definitive and extraembryonic endoderm. It is an
outstanding question whether pluripotency in HESC is fine-tuned
by REX1-mediated regulation of HERV-K similar to the situation
in the mouse.
In human pluripotent cells, cellular heterogeneity has been
studied mainly in the context of standardization of human induced
pluripotent stem (HiPS) cells. HiPS are pluripotent cells with
characteristics identical to or very similar to HESC, which can
be generated by reprograming of adult cells (14, 165). Differ-
ent lines of HiPS cells display a higher level of variability at the
level of gene expression and epigenetic signatures compared to
ES from either mouse or human. This can be attributed to dif-
ferences in derivation methods including donor cell types, and to
the differences in age, genetic background, and pathology states
of the donors (14). However, overcoming longstanding impedi-
ments, HESC with properties similar to ground state pluripotency
described in the mouse have recently been derived (166). Condi-
tions to generate such ground state HESC/HiPS cells are expected
to diminish the cellular heterogeneity observed at the gene expres-
sion level. As HERV-K expression is very high in HESC (159), it will
be of interest to see if ERV-driven reporters could now be used to
classify HESC according to potency levels similar to mouse ES cells.
An important difference between mouse and HESCs also is the
latter’s capacity for trophectodermal differentiation. Placentation
is a relatively recent event on the scale of evolution, and the diver-
sity of placental morphology among mammalian species suggests
that it has appeared various times independently (167). Moreover,
generic difference in genome management may already underlie
different timing of ZGA between mouse and human (161), and
posterior separation of lineages. Such species-specific differences
may also have altered cis-acting functions and regulation of ERV-L
in different species.
CONCLUDING REMARKS: RELATIONSHIPS WITH CANCER
We finally comment on the relevance of HERV -directed transcrip-
tion and the mechanisms that control it for human cancer biology.
Cancerous cells often display genome-wide loss of DNA methy-
lation resulting from a loss of methylation on TE (24, 168), and
progressive loss of silencing. Similar to DNA hypomethylation,
dramatic changes in histone modification patterns are rampant
(169). Relaxation of alternative silencing mechanisms described
here may re-activate TE/ERVs elements in tumors, as initially
demonstrated in mice (170).
Mechanisms that explain how the activity of HERVs may con-
tribute to tumor formation have been reviewed elsewhere [i.e.,
Ref. (8, 171)]. Both de novo transposition events and deregula-
tion of HERV-derived control elements may affect the expres-
sion of tumor suppressor genes or (proto-)oncogenes nearby.
Occasionally, proto-oncogenes may be incorporated in variant
HERV. As these genes control cell growth and proliferation, their
deregulation may give rise to a malignant or transformed cell
with enhanced growth characteristics. In addition, HERV-encoded
ENV proteins may provide cell fusion properties that help the
transition toward metastasis or help tumor cells evade an anti-
tumoral immune response by virtue of its immunosuppressive
properties (172). Alternatively, uncontrolled expression of TE has
been related to genome instability caused by DNA breaks and
chromosome translocations. Deregulation of retroviral elements
in tumors might be indicative of improper activity of genome
stability mechanisms, potentially preceding insult resulting from
de-stabilization. RT activity (encoded in HERV) might be used
as a measure of the extent of ERV/TE-deregulation (173), and be
instrumental in tumor classification. Moreover, as pluripotency
markers are overexpressed in tumor cell lines coinciding with
increased RT activity (173), the level of RT activity might even
indicate the presence of tumor stem cells.
The potential contribution of HERV to tumor formation
should also be taken into account in the context of gene therapy,
as insertion of new genes in a location that relieves HERV silenc-
ing may trigger these activation processes. Moreover, as modified
viruses are commonly used as vectors for gene therapy, the relief
of HERV silencing commonly associated with viral infections and
inflammation (174) constitutes a risk factor for gene therapy by
itself and HERV-encoded proteins might provide essential proteins
that allow the mobilization of replication-defective provirus.
YY1 overexpression has been reported in tumors, and overex-
pression levels are related to clinical progression (175). Differences
(usually overexpression) of YY1 transcript levels in tumor tissue
relative to normal counterparts have also been extracted by com-
putational analysis from gene expression omnibus (GEO) datasets
(176). It seems obvious to presume that YY1’s well documented
function in the regulation of gene networks that control cell prolif-
eration underlies its role in oncogenesis. However,YY1 participates
in distinct mechanisms potentially related to oncogenesis, includ-
ing increased mutagenesis, regulation of chromosome dynamics
(such as imprinting and X-inactivation), and DNA repair and
chromosome segregation (177). We suggest that the contribu-
tion of YY1-family proteins to oncogenesis may as well reside in
silencing of TE (and ERV in particular).
The judge is still out on the question whether HERV activation
is a triggering event in tumor development, or whether they are
upregulated as a consequence of previous alterations associated
with tumor development, i.e., genomic instability or demethyla-
tion. So far, the expression of HERVs has been linked to germ cell
tumors, breast cancer, ovarian cancer, and melanoma [reviewed in
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Ref. (8, 10)]. Enhanced knowledge of the mechanisms that control
HERV expression will aid the understanding of how heteroge-
neous HERV activity levels may contribute to differences among
individuals in susceptibility to cancer.
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